Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15570996 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL13562172 | 0.92 | CHRM2 (0.42) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL20689796 | 0.86 | CHRM2 (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL433051 | 0.85 | CHRM2 (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL21452961 | 0.85 | CHRM2 (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL3744023 | 0.85 | CHRM2 (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL16209734 | 0.83 | KDM4E (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL25037249 | 0.83 | CHRM2 (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL26663407 | 0.83 | CHRM2 (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL14919611 | 0.83 | KDM4E (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250382296-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4567036-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| CN-119744263-A | PRMT5 inhibitors | 北京望实智慧科技有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230192679-A1 | CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192679-A1 | CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023114507-A1 | CRYSTALLINE FORM OF N-(6-AMINO-5-METHYLPYRIDIN-3-YL)-2-(BENZO[D]THIAZOL-5-YL)-5-METHYLPIPERIDIN-1-YL)-2-OXOACETAMIDE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382296-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PRMT5, PRMT1, PRMT8 | CHRM2 4511/4885CHRM1 4026/4885CHRM3 4485/4885 |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | CHRM2 2572/4885CHRM1 1931/4885CHRM3 3001/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | CHRM2 4479/4885CHRM1 4361/4885CHRM3 4610/4885 |
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | ABCG2, F12, CYP2C9 | CHRM2 72/4885CHRM1 36/4885CHRM3 255/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CHRM2 13/4885CHRM1 7/4885CHRM3 69/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRM2 13/4885CHRM1 7/4885CHRM3 69/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | CHRM2 894/4885CHRM1 654/4885CHRM3 1499/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CHRM2 13/4885CHRM1 7/4885CHRM3 69/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CHRM2 13/4885CHRM1 7/4885CHRM3 69/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRM2 13/4885CHRM1 7/4885CHRM3 69/4885 |
| US-20230192679-A1 | CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | PRMT5, PRMT1, PRMT3 | CHRM2 1887/4885CHRM1 1981/4885CHRM3 2017/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | CHRM2 158/4885CHRM1 134/4885CHRM3 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.